Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)

Abstract

In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone.

Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America

“…The literature search identified 11 trial reports, representing 12 RCTs that compared postoperative chemotherapy with surgery alone [12][13][14][15][16][17][18][19][20][21][22]. All of these studies, except for one very recently published trial [22], were part of the meta-analyses described above and will not be discussed further.…”

Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

“…There is no defined standard that addresses the number of cycles of adjuvant chemotherapy that are required for the maximal response after gastric cancer resection. Previous studies have reported that patients with stomach cancer had no survival benefit from 3 to 5 courses of adjuvant chemotherapy after radical gastrectomy (De Vita et al, 2007;Di Costanzo et al, 2008;Kulig et al, 2010). Neri et al (2001) investigated whether 7 cycles of adjuvant chemotherapy led to a longer median survival time than the surgery-only group.…”

Multidisciplinary management of gastric and gastroesophageal cancers

“…After 3-year follow-up and rare grade 3/4 toxicities, overall survival and relapse-free survival favored the S-1 arm, with 81.1% vs 70.1% (P = 0.0015) and 72.2% vs 60.1% (P = 0.0001), respectively [21] (Figure 1). The Italian Gruppo Oncologico dell'Italia Meridionale (GOIM) study found also in trend some positive results for epirubicin/etoposide/5-FU/folinic acid (FA) in > D1 resected patients [22] . Adjuvant radiotherapy alone has failed over the last decades to improve treatment results and patient outcome.…”

“…In addition, major surgery such as total gastrectomy delays the start of postoperative systemic chemotherapy by a month or more, potentially giving microscopic residual diseases an opportunity to proliferate. On the other hand, it has been suggested that patho- Figure 1 Survival of S-1 monotherapy versus surgery alone for stage Ⅱ/Ⅲ gastric cancer patients after curative D2 gastrectomy (ACTS-GC study) [22] .…”